News

Sermonix to Co-sponsor ‘Candid Conversations’ Patient Advocacy Panel With Breastcancer.org at San Antonio Breast Cancer Symposium

Discussion will examine sexual health and intimacy, bone health, joint and muscle pain, and quality of life issues in metastatic breast cancer COLUMBUS, Ohio, Dec. 03, 2019 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female-specific oncology products in the precision medicine metastatic breast cancer arena, [...]
Read more

Sermonix to Present Poster on Oncologists’ Perception of Sexual Intimacy Issues in Treatment of Metastatic Breast Cancer at 2019 North American Menopause Society Annual Meeting

Sept. 26 presentation in Chicago demonstrates the need for improvement in practitioners’ understanding of patients’ intimacy concerns COLUMBUS, Ohio, Sept. 25, 2019 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female-specific oncology products in the precision medicine metastatic breast cancer arena, today [...]
Read more

Sermonix Doses First Patient in Phase 2 Clinical Trial of Lasofoxifene for Targeted Precision Medicine Treatment of Women With ESR1 Mutations in Metastatic Breast Cancer

Biopharmaceutical company is partnering with Sysmex Inostics to identify appropriate study candidates with the OncoBEAM™ ESR1 liquid biopsy test COLUMBUS, Ohio, Sept. 23, 2019 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female-specific oncology products in the precision medicine metastatic breast cancer [...]
Read more

Sermonix Poster Presentation at 2019 ASCO Annual Meeting Demonstrates Promise for Lasofoxifene in Treating ER+ Metastatic Breast Cancer Patients With ESR1 Mutations

Sermonix-sponsored University of Chicago preclinical investigation demonstrated: Lasofoxifene alone was significantly more effective than fulvestrant at inhibiting metastasis of both MCF7-Y537S and D538G tumors to the lungs and liver. Lasofoxifene, in combination with palbociclib, was more effective than fulvestrant + palbociclib at reducing primary tumor growth. Lasofoxifene + palbociclib [...]
Read more

Lasofoxifene Shows Promise as Treatment for ER-Positive Metastatic Breast Cancer

CHICAGO—Findings suggest that lasofoxifene, in combination with CDK4/6 inhibitors like palbociclib, is a promising approach for the treatment of endocrine therapy resistant ER+ metastatic breast cancer patients (Abstract 1056). “Lasofoxifene is a legacy molecule originally developed for the treatment of osteoporosis and vaginal dryness,” noted Geoffrey L. Greene, PhD, Virginia and [...]
Read more

Sermonix Receives FDA Fast Track Designation for Investigational Drug Lasofoxifene

Designation allows for expedited development and review of lasofoxifene as a potential precision medicine treatment for women who have estrogen receptor-positive (ER+) metastatic breast cancer with an ESR1 mutation COLUMBUS, Ohio, May 28, 2019 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development of female-specific [...]
Read more

Sermonix to Present Poster on ‘Lasofoxifene as a Potential Treatment for ER+ Metastatic Breast Cancer’ at 2019 ASCO Annual Meeting

Biopharmaceutical company studied combination of lasofoxifene and CDK4/6 inhibitor palbociclib versus fulvestrant and palbociclib in animal models. COLUMBUS, Ohio (May 7, 2019) – Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific oncology products, today announced that it will present a poster on the [...]
Read more

Sermonix Pharmaceuticals Adds Three New Members to Its Board of Directors

Richard U. DeSchutter, Michael A. Friedman and Stephen Rubino bring decades of diverse C-level experience to biopharmaceutical company conducting a Phase 2 clinical trial for the precision medicine treatment of metastatic breast cancer COLUMBUS, Ohio (April 23, 2019) – Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of [...]
Read more

Sermonix to Present at Boston Oncology Investor Conference on Potential for Lasofoxifene in Metastatic Breast Cancer Treatment

COLUMBUS, Ohio, March 11, 2019 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific oncology products, today announced that founder and Chief Executive Officer Dr. David Portman will present at the Boston Oncology Investor Conference. Dr. Portman will discuss the Phase 2 study of [...]
Read more

Sermonix to Present Poster at ENDO 2019 on Lasofoxifene’s ‘Potent Anti-Tumor Activity’ in ESR1 Hormone-Resistant Breast Cancer

Biopharmaceutical company collaborated with Ben May Department for Cancer Research at University of Chicago to study efficacy of lasofoxifene COLUMBUS, Ohio, March 04, 2019 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific oncology products, today announced it will present a [...]
Read more